Perrin E. Romine

Perrin E. Romine

Auto-generated profile, based on publicly available information

Perrin E. Romine

Swedish Cancer Institute, Seattle, Washington

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
PRPerrin E. Romine
Perrin E. Romine
QSQin Sun
Qin Sun
CFCatherine Fedorenko
Catherine Fedorenko
LLLi Li
Li Li
MTMariel Tang
Mariel Tang
RMRenato G. Martins
Renato G. Martins
PURPOSE: Time from diagnosis to treatment has been associated with worse survival outcomes in non–small-cell lung cancer (NSCLC). However, little is known about the impact of delay in time to diagnosis. We aimed to evaluate the impact of time from radiographic suspicion to histologic diagnosis on survival outcomes using the US SEER-Medicare population database. METHODS: We identified patients from the SEER-Medicare data set diagnosed with any stage NSCLC between January 1, 2011, and December 31, 2015, who received stage-appropriate treatment and had a computed tomography scan within 1 year of diagnosis. Time to confirmation was determined as the interval between most recent computed tomography imaging and date of histologic diagnosis. Our primary outcome was overall survival (OS). RESULTS: In total, 10,824 eligible patients were identified. The median time to confirmation was 20 (range 0-363) days. Using multivariate Cox regression models, longer time to confirmation was associated with improved OS in all comers driven by stage IV patients after adjustment for age, sex, diagnosis year, histology, and comorbidity index. In a separate landmark analysis excluding patients deceased within 6 months of diagnosis, the association between time to diagnosis and survival was no longer evident. CONCLUSION: Time to confirmation of NSCLC was inversely associated with OS in this US SEER population study. This association was lost when patients deceased within 6 months of diagnosis were excluded, suggesting that retrospective registry-claims databases may not be the optimal data source to study time to diagnosis as a quality metric because of the unaccounted confounding effects of tumor behavior. Prospective evaluations of clinically enriched data sources may better serve this purpose.

1 November 2022 in Journal of Medical Imaging
Verified
Journal Article
Closed access
PDF file
JCJaryd R. Christie
Jaryd R. Christie
ODOmar Daher
Omar Daher
MAMohamed Abdelrazek
Mohamed Abdelrazek
PRPerrin E. Romine
Perrin E. Romine
RMRichard Adam Malthaner
Richard Adam Malthaner
SMSarah Mattonen
Sarah Mattonen
PurposeWe developed a model integrating multimodal quantitative imaging features from tumor and nontumor regions, qualitative features, and clinical data to improve the risk stratification of patients with resectable non-small cell lung cancer (NSCLC).ApproachWe retrospectively analyzed 135 patients [mean age, 69 years (43 to 87, range); 100 male patients and 35 female patients] with NSCLC who underwent upfront surgical resection between 2008 and 2012. The tumor and peritumoral regions on both preoperative CT and FDG PET-CT and the vertebral bodies L3 to L5 on FDG PET were segmented to assess the tumor and bone marrow uptake, respectively. Radiomic features were extracted and combined with clinical and CT qualitative features. A random survival forest model was developed using the top-performing features to predict the time to recurrence/progression in the training cohort (n = 101), validated in the testing cohort (n = 34) using the concordance, and compared with a stage-only model. Patients were stratified into high- and low-risks of recurrence/progression using Kaplan–Meier analysis.ResultsThe model, consisting of stage, three wavelet texture features, and three wavelet first-order features, achieved a concordance of 0.78 and 0.76 in the training and testing cohorts, respectively, significantly outperforming the baseline stage-only model results of 0.67 (p < 0.005) and 0.60 (p = 0.008), respectively. Patients at high- and low-risks of recurrence/progression were significantly stratified in both the training (p < 0.005) and the testing (p = 0.03) cohorts.ConclusionsOur radiomic model, consisting of stage and tumor, peritumoral, and bone marrow features from CT and FDG PET-CT significantly stratified patients into low- and high-risk of recurrence/progression.

3 May 2023 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
MTMatthew Triplette
Matthew Triplette
MBMeagan C. Brown
Meagan C. Brown
MSMadison Snidarich
Madison Snidarich
JBJehan Z. Budak
Jehan Z. Budak
NGNicholas Giustini
Nicholas Giustini
KCKristina Crothers
Kristina Crothers

14 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PRPerrin E. Romine
Perrin E. Romine
RMRenato G. Martins
Renato G. Martins
KEKeith Eaton
Keith Eaton
DWDouglas E. Wood
Douglas E. Wood
FBFatemeh Behnia
Fatemeh Behnia
HVHubert J. Vesselle
Hubert J. Vesselle
Neoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron emission tomography (PET) scans may offer early prognostic or predictive value after one cycle of induction chemotherapy. In this phase II non-randomized trial, patients with AJCC version 6 stage IB to IIIB operable NSCLC were treated with 3 cycles of cisplatin and pemetrexed neoadjuvant chemotherapy. Patients underwent FDG-PET scanning prior to and 18 to 21 days after the first cycle of chemotherapy. Investigators caring for patients were blinded to results, unless the scans showed evidence of disease progression. FDG-PET response was defined prospectively as a ≥ 20% decrease in the SUV of the primary lesion. Between October 2005 and February 2010, 25 patients enrolled. Fifty two percent were female, 88% white, and median age was 62 years. Histology was divided into adenocarcinoma 66%, not otherwise specified (NOS) 16%, squamous cell 12%, and large cell 4%. Stage distribution was: 16% IB, 4% IIB, and 79% IIIA. Treatment was well tolerated and only one patient had a grade 4 toxicity. The median follow up was 95 months. The 5 year progression free survival (PFS) and overall survival (OS) for the entire population were 54 and 67%, respectively. Eighteen patients had a baseline FDG-PET scan and a repeat scan at day 18–21 available for comparison. Ten patients (56%) were considered metabolic responders on the day 18–21 FDG-PET scan. Responders had a 5 year PFS and OS of 60 and 70%, respectively, while the percentage for non-responders was 63 and 75% (p = 0.96 and 0.85). This phase II trial did not demonstrate that a PET scan after one cycle of chemotherapy can predict survival outcomes of patients with NSCLC treated with neoadjuvant chemotherapy. NCT00227539 registered September 28th, 2005.

19 November 2021 in Oral Oncology
Verified
Journal Article
Closed access
PRPerrin E. Romine
Perrin E. Romine
JVJenna Voutsinas
Jenna Voutsinas
VWVicky Wu
Vicky Wu
MTMicah Tratt
Micah Tratt
JLJay Liao
Jay Liao
CRCristina Rodriguez
Cristina Rodriguez

1 January 2019 in The American Journal of Medicine
Verified
Journal Article
Closed access
PRPerrin E. Romine
Perrin E. Romine
KEKeith D. Eaton
Keith D. Eaton
KPKelly G. Paulson
Kelly G. Paulson
RHRouba Hadi
Rouba Hadi
DPDouglas S. Paauw
Douglas S. Paauw